Stifel Financial Corp Acquires 10,924 Shares of Hologic, Inc. (NASDAQ:HOLX)

Stifel Financial Corp raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 115.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,354 shares of the medical equipment provider's stock after purchasing an additional 10,924 shares during the period. Stifel Financial Corp's holdings in Hologic were worth $1,658,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its holdings in Hologic by 11.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,804 shares of the medical equipment provider's stock valued at $357,000 after purchasing an additional 487 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Hologic by 20.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 251,869 shares of the medical equipment provider's stock valued at $18,701,000 after purchasing an additional 42,661 shares during the last quarter. HB Wealth Management LLC boosted its position in Hologic by 6.1% in the second quarter. HB Wealth Management LLC now owns 5,795 shares of the medical equipment provider's stock valued at $430,000 after buying an additional 332 shares in the last quarter. Banco Santander S.A. grew its stake in shares of Hologic by 5.8% during the second quarter. Banco Santander S.A. now owns 4,670 shares of the medical equipment provider's stock worth $347,000 after buying an additional 258 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Hologic by 4.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 353,782 shares of the medical equipment provider's stock worth $26,268,000 after buying an additional 16,387 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They set a "peer perform" rating on the stock. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Leerink Partners decreased their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target on the stock. Finally, UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $89.50.

Hologic Trading Up 1.3 %

NASDAQ:HOLX opened at $71.65 on Friday. The firm's 50 day moving average is $78.65 and its 200 day moving average is $78.52. Hologic, Inc. has a 12 month low of $70.36 and a 12 month high of $84.67. The stock has a market capitalization of $16.26 billion, a PE ratio of 21.52, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. The business's revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.75% of the stock is owned by corporate insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.